Science & Technology Partners’s Neurocrine Biosciences NBIX Stock Holding History

Science & Technology Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.4M	Buy	+79,724	New	+$11.8M	2.26%	18

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Science & Technology Partners's NBIX Position: Q2 2026 in Review

Science & Technology Partners opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 79,724 shares worth $13.4M. The stake represents 2.26% of the portfolio and ranks #18 among its holdings.

771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Science & Technology Partners held 79,724 shares of Neurocrine Biosciences worth $13.4M as of Q2 2026.
Neurocrine Biosciences was a new Science & Technology Partners position in Q2 2026.
Neurocrine Biosciences made up 2.26% of Science & Technology Partners's portfolio in Q2 2026, its #18 holding.
771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Science & Technology Partners's 13F filing for Q2 2026, filed 14 Aug 2026.